德国关于茴香酰化纤溶酶原链激酶激活剂复合物与肝素治疗急性心肌梗死的多中心试验。
The German multicenter trial of anisoylated plasminogen streptokinase activator complex versus heparin for acute myocardial infarction.
作者信息
Meinertz T, Kasper W, Schumacher M, Just H
机构信息
Medical Clinic III, University of Freiburg, Federal Republic of Germany.
出版信息
Am J Cardiol. 1988 Sep 1;62(7):347-51. doi: 10.1016/0002-9149(88)90956-3.
A multicenter randomized trial of anisoylated plasminogen streptokinase activator complex (APSAC) versus heparin in patients with acute myocardial infarction of less than 4 hours' duration was undertaken in 19 hospitals. Of the 313 patients, 151 received heparin and 162 APSAC (30 U as intravenous injection). Within 28 days of hospital stay, 19 deaths (12.6%) occurred in the heparin group and 9 deaths (5.6%) in the APSAC group (p = 0.032). After 24 hours, patients in the APSAC group had a significantly lower incidence of cardiogenic shock (3.2 vs 9.5%, p = 0.031), asystole (3.8 vs 10.8%, p = 0.015) and need for resuscitation (5.1 vs 11.5%, p = 0.039). There was no difference in global and infarct-related ejection fraction between the 2 groups. Thus, APSAC favorably influences prognosis and clinical course in hospital.
在19家医院开展了一项多中心随机试验，比较茴香酰化纤溶酶原链激酶激活剂复合物（APSAC）与肝素对病程小于4小时的急性心肌梗死患者的疗效。313例患者中，151例接受肝素治疗，162例接受APSAC治疗（静脉注射30单位）。住院28天内，肝素组有19例死亡（12.6%），APSAC组有9例死亡（5.6%）（p = 0.032）。24小时后，APSAC组心源性休克发生率显著较低（3.2%对9.5%，p = 0.031），心脏停搏发生率较低（3.8%对10.8%，p = 0.015），复苏需求较低（5.1%对11.5%，p = 0.039）。两组的整体及梗死相关射血分数无差异。因此，APSAC对住院患者的预后和临床病程有积极影响。
Zotero 插件